PRESS RELEASE
News
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire initiates Phase 1 trial for high-dose aspirin formulation to target acute myocardial infarction. Trial to evaluate safety, pharmacokinetics, pharmacodynamics, with fast track FDA application -
-
-
PRESS RELEASE
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Immunic, Inc. announces pricing of $5.1 million registered direct offering led by Aberdeen Investments for clinical pipeline of therapies. Funds to be used for clinical trials and operations -
PRESS RELEASE
Bausch Health, Canada Inc. et l’Alliance pharmaceutique pancanadienne signent une lettre d’intention concernant pour la couverture par les régimes publics d’assurance médicaments du traitement pour l’acné vulgaire (Pr)CABTREO(MC) (gel de phosph
Bausch Health, Canada Inc. signe une lettre d'intention avec l'Alliance pharmaceutique pancanadienne pour la couverture du gel CABTREO dans les régimes publics d'assurance médicaments du Canada, offrant un traitement topique innovant contre l'acné vulgaire -
PRESS RELEASE
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
Bausch Health Canada signs agreement with pCPA for PrCABTREO gel to be covered by Canadian public drug plans. CABTREO is a triple-combination topical treatment for acne vulgaris -
-
-
PRESS RELEASE
Silver X Announces Filing of NI 43-101 Technical Report for Previously Announced Mineral Resource Estimate for the Nueva Recuperada Project, Including Plata Mining Unit
Silver X Mining Corp. announces significant increase in mineral resource estimate for Nueva Recuperada Project in Peru. Independent NI 43-101 Report details growth in silver, zinc, lead resources
